Details for Patent: 8,143,225

Title:	Pharmaceutical compositions including low dosages of desmopressin
Abstract:	The present invention is directed to a pharmaceutical composition comprising 0.5 ng to 20 .mu.g desmopressin and a pharmaceutically acceptable carrier. The present invention is also directed to a pharmaceutical composition comprising desmopressin and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is effective to establish a steady plasma/serum desmopressin concentration in the range of from about 0.1 picograms desmopressin per mL plasma/serum to about 10.0 picogram desmopressin per mL plasma/serum. Articles of manufacture and methods of using the above invention are also disclosed.
Inventor(s):	Fein; Seymour (New Canaan, CT)
Assignee:	Allergan, Inc. (Irvine, CA)
Filing Date:	Jul 15, 2008
Application Number:	12/173,072
Claims:	1. A patch adapted for intradermal administration of desmopressin to a patient, the patch comprising desmopressin and a pharmaceutically acceptable carrier in a dosage form that dispenses from 0.5 ng up to 2 .mu.g desmopressin intradermally. 2. The patch of claim 1, wherein the patch comprises a depot of desmopressin. 3. The patch of claim 1, wherein the dosage form is formulated to establish a plasma/serum desmopressin concentration within the range from about 0.1 picograms desmopressin per ml plasma/serum to a maximum of 10.0 picograms per ml plasma/serum and to decrease urine production. 4. The patch of claim 3, wherein the dosage form is formulated to establish a plasma/serum desmopressin concentration within the range from about 0.5 picograms desmopressin per ml plasma/serum to a maximum of 5.0 picograms per ml plasma/serum. 5. The patch of claim 3, wherein the dosage form is formulated to establish a plasma/serum desmopressin concentration within the range from about 0.1 picograms desmopressin per ml plasma/serum to a maximum of 10.0 picograms per ml plasma/serum for a time between four and six hours. 6. The patch of claim 1, wherein the dosage form is effective to produce an antidiuretic effect lasting for a maximum of between about 4 and about 6 hours. 7. The patch of claim 1, wherein the dosage form is effective to produce a urine osmolality ranging above about 300 mOsm/kg for less than about 5 hours after administration.